Trial Investigating Personalized Cancer Immunotherapy Achieves 94% Manufacturing Success Rate [04-February-2020] IRVINE, Calif. , Feb. 4, 2020 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that it has reached its patient enrollment target in the Company’s Phase 2 clinical trial for gliobla
February 4, 2020
· 4 min read